“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will...
On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on...
How will a rare disease diagnosis affect your family? Today's Few & Far Between episode features Bo Bigelow, Chairman at the Foundation for USP7-Related...